AUTHORS
Sean Bowden, MD, Pedro Luiz Lage Bodour Danielian, MD, MPH2, Lauren Turecki, MD3, Mara Epstein, ScD4, Sakiko A Suzuki, MD5, Jan Cerny, MD, PhD6, Muthalagu Ramanathan, MD7, Andrew Gillis-Smith, MD8, Laurie K Pearson, MD9, Shyam A Patel, MD, PhD10, Poorva Bindal, MD11
AFFILIATIONS
1 University of Massachusetts, Worcester, Massachusetts, United States
2 University of Connecticut, Farmington, Connecticut, United States
3 University of Massachusetts, Worcester, Massachusetts, United States
4 University of Massachusetts, Worcester, Massachusetts, United States
5 University of Massachusetts, Worcester, Massachusetts, United States
6 University of Massachusetts, Worcester, Massachusetts, United States
7 University of Massachusetts, Worcester, Massachusetts, United States
8 University of Massachusetts, Worcester, Massachusetts, United States
9 University of Massachusetts, Worcester, Massachusetts, United States
10 University of Massachusetts, Worcester, Massachusetts, United States
11 University of Massachusetts, Worcester, Massachusetts, United States
ABSTRACT
Transformed follicular lymphoma (tFL) is an aggressive lymphoma arising from histologic transformation of follicular lymphoma and is often characterized by treatment resistance, substantial prior therapy exposure, and competing risks of disease progression and treatment-related morbidity. CD19-directed chimeric antigen receptor (CAR) T-cell therapy can provide durable disease control, but outcomes remain heterogeneous and tools to identify patients at risk for non-relapse complications are limited. The Hematopoietic Cell Transplantation–Specific Comorbidity Index (HCT-CI) is widely used to quantify baseline organ dysfunction and comorbidity burden before transplantation. Although a Cellular Therapy Comorbidity Index (CT-CI) has recently been developed for patients receiving CAR T-cell therapy for large B-cell lymphoma, its applicability to tFL remains uncertain. A prior Center for International Blood and Marrow Transplant Research (CIBMTR) analysis found that HCT-CI ≥3 was associated with inferior progression-free survival (PFS) after CAR T-cell therapy for tFL; however, whether HCT-CI adds prognostic information beyond age and Karnofsky Performance Status (KPS) has not been evaluated. We assessed the incremental prognostic utility of HCT-CI for all-cause mortality (ACM), PFS, and non-relapse mortality (NRM).
We performed a secondary analysis of a publicly available CIBMTR dataset including adults aged ≥18 years with relapsed/refractory tFL who received commercial CD19-directed CAR T-cell therapy as their first cellular therapy between 2017 and 2023. Cox proportional hazards models evaluated ACM and PFS, and a cause-specific Cox model evaluated NRM. HCT-CI was categorized as 0, 1–2, or ≥3. KPS was available in the public dataset only as 90–100, <90, or not reported and was therefore modeled as 90–100 versus <90. Models included age and KPS, with and without HCT-CI. Incremental model performance was assessed using likelihood ratio tests (LRTs) and Akaike information criterion (AIC). Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated.
Of 923 patients in the dataset, 833 had complete HCT-CI and KPS data and comprised the analytic cohort. Mean age was 63 years, 60.0% were male, 81.9% were White, 2.9% were Black, and 3.1% were Asian; 9.8% were Hispanic/Latino, and race was not reported in 11.2%. KPS was <90 in 55.7%. HCT-CI scores were 0 in 31.5%, 1–2 in 32.1%, and ≥3 in 36.5%. The principal finding was that HCT-CI was independently associated with NRM and significantly improved model performance beyond age and KPS. Compared with HCT-CI=0, scores of 1–2 and ≥3 were associated with approximately twofold higher NRM risks (HR, 1.97; 95% CI, 1.16–3.37 and HR, 2.16; 95% CI, 1.29–3.61, respectively). Adding HCT-CI to a model containing age and KPS significantly improved model fit for NRM (LRT p=0.006; AIC, 1394.6 vs 1400.8). In contrast, HCT-CI was not independently associated with ACM or PFS. It did not improve the ACM model (LRT p=0.25; AIC, 4377.2 vs 4376.0). For PFS, adding HCT-CI suggested a modest but statistically nonsignificant improvement in model fit (LRT p=0.10; AIC, 5569.1 vs 5569.8).
HCT-CI provided progressive prognostic information specifically for NRM beyond age and KPS among patients with tFL receiving CAR T-cell therapy. Its lack of meaningful incremental value for ACM or PFS suggests that baseline comorbidity burden may be more informative for identifying vulnerability to fatal non-relapse complications than for predicting lymphoma control. HCT-CI may complement performance status during pre-CAR T evaluation to identify patients who could benefit from intensified supportive care and toxicity monitoring, but it should not be used in isolation to determine treatment eligibility. Future studies should validate these findings, compare HCT-CI with CT-CI, and evaluate the associations between individual comorbidities and specific causes of NRM, including fatal infections and immune effector cell–associated toxicities, with the goal of reducing NRM risk in this vulnerable population.
Disclosure: Data used from the database from CIBMTR was not reviewed by CIBMTR and findings here do not reflect their own conclusions.
DISCLOSURES
Sean Bowden, MD: No relevant conflicts of interest to declare.